Please login to the form below

Not currently logged in
Email:
Password:

Tobira Therapeutics

This page shows the latest Tobira Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Allergan buys regenerative medicine firm LifeCell for $2.9bn

Allergan's other deals in 2016 have included a $1.7bn acquisition of Tobira Therapeutics - which gave it two drug candidates for non-alcoholic steatohepatitis (NASH) - a $639m takeover of dermatology

Latest news

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    Along with selonsertib, Gilead is also developing an FXR agonist called GS-9674 in phase I trials and acquired a wholly-owned subsidiary of Nimbus Therapeutics for $1.2bn earlier this ... Allergan has been building a pipeline of candidates through a

  • Allergan buys two NASH drug developers in one day Allergan buys two NASH drug developers in one day

    Allergan buys two NASH drug developers in one day. More than $1.7bn paid for Tobira Therapeutics and Akarna Therapeutics. ... Allergan has gone on the acquisition trail once again, stumping up more than $1.7bn for non-alcoholic steatohepatitis (NASH)

  • A competitive edge

    TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Ampyra (Acorda Therapeutics). Multiple

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Hogging the headlines …. Featuring in two entries in the September Deal Watch table, Allergan was busy splashing the cash with a $1.7bn acquisition of Tobira Therapeutics, hotly followed by the ... 1, 710. Tobira Therapeutics / Allergan. Acquisition

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics